Lymphocytoma, most often called lymphocytoma cutis, is a benign skin condition in which immune cells called lymphocytes build up in the skin and form a nodule or plaque that can look alarmingly like a skin cancer, specifically a cutaneous lymphoma. It belongs to a broader family of conditions known as pseudolymphomas, where “pseudo” is the operative word: the lesion mimics cancer under the microscope and to the naked eye but is not malignant.1PubMed Central. Pseudolymphoma versus lymphoma: An important diagnostic decision The most well-known trigger is infection with Borrelia bacteria spread by ticks, making lymphocytoma one of the less-recognized faces of Lyme disease, but drugs, tattoos, vaccinations, and sometimes no identifiable cause can produce the same kind of lesion.
What Causes Lymphocytoma
The best-studied trigger is Borrelia infection, the same group of bacteria responsible for Lyme disease. In Europe, borrelial lymphocytoma is predominantly caused by Borrelia afzelii, a species carried by the Ixodes ricinus tick.2PubMed. Borrelial lymphocytoma A tick bite is reported in roughly half of patients who develop the lesion, and the lymphocytoma tends to appear at or near the bite site.3SpringerLink (Wien Klin Wochenschr). Borrelial lymphocytoma In many cases the lymphocytoma shows up alongside erythema migrans, the classic bull’s-eye rash of early Lyme disease, but it can also be the only visible sign of infection, which is part of what makes it tricky to catch.
When Borrelia is not involved, the list of potential triggers is surprisingly varied. Drugs are one of the more common culprits. Anticonvulsants, certain antibiotics, antiarrhythmic medications, and nonsteroidal anti-inflammatory drugs (NSAIDs) have all been documented as causes. Beyond drugs, tattoo pigments, vaccinations, and ordinary insect bites can provoke the same exaggerated immune cell buildup in the skin.4PubMed Central. Upadacitinib in refractory cutaneous pseudolymphoma: A case report And then there are cases where no trigger can be identified at all, termed idiopathic lymphocytoma cutis. These are the diagnostically frustrating ones, because without a clear cause, the clinician has fewer clues to rule out actual lymphoma.
What It Looks Like and Where It Shows Up
A typical lymphocytoma cutis lesion is a firm, dome-shaped nodule or slightly raised plaque. It ranges from reddish to bluish-red, sometimes with a violet tinge, and it usually measures a few centimeters across. The lesion is generally painless and slow-growing, which paradoxically can delay medical attention because it does not feel urgent.5PubMed Central. Idiopathic lymphocytoma cutis: a diagnostic dilemma Most of the time the lesion is solitary, meaning you get one nodule rather than a scattered rash.
What makes borrelial lymphocytoma distinctive is its tendency to favor specific body sites depending on the patient’s age. In children, the earlobe is the classic location. In adults, the breast, particularly the nipple or areola, is the most common site. The scrotum is another recognized predilection site.6PubMed Central. Borrelial Lymphocytoma Cutis with Septo-Lobular Panniculitis Involving Bilateral Ear Lobes in a Child: A Rare Presentation in a Non-Endemic Region Idiopathic cases, on the other hand, often crop up on exposed areas like the face and neck, without the same tight anatomical preference.7PubMed Central. Idiopathic lymphocytoma cutis: a diagnostic dilemma
A child with an unexplained bluish-red nodule on the earlobe, particularly in a region where Lyme disease circulates, should immediately raise suspicion for borrelial lymphocytoma. This scenario is more common in parts of Central and Western Europe than it is in North America, where the Borrelia species that typically cause this manifestation are far less prevalent.8PubMed Central. Borrelial lymphocytoma cutis: a diagnostic dilemma
Why the Distinction from Lymphoma Matters So Much
The whole reason lymphocytoma cutis commands serious attention is that it can be nearly indistinguishable, both visually and under the microscope, from a genuine cutaneous B-cell lymphoma. The treatment paths for these two diagnoses could not be more different: one calls for antibiotics or sometimes no treatment at all, and the other may require chemotherapy, radiation, or long-term oncologic follow-up. Getting the distinction wrong in either direction is a problem. A misdiagnosis of cancer subjects someone to unnecessary treatments and psychological burden. A missed lymphoma, on the other hand, allows a malignancy to progress unchecked.
The lymphoma most commonly confused with lymphocytoma cutis is primary cutaneous marginal zone B-cell lymphoma. These are low-grade cancers that grow slowly and tend to recur, but they still require different management from a benign pseudolymphoma.9PubMed. Primary cutaneous marginal zone B-cell lymphoma: clinical and histological aspects Both conditions can present as a pinkish or reddish nodule on the skin, and both show dense collections of B lymphocytes on biopsy. So a dermatologist or pathologist looking at either one is dealing with overlapping clinical and microscopic features.
How Lymphocytoma Is Diagnosed
Diagnosis requires a skin biopsy. There is no blood test or clinical shortcut that reliably confirms lymphocytoma cutis. Once the tissue sample is under a microscope, several features point toward a benign pseudolymphoma rather than a true lymphoma.
Histologically, lymphocytoma cutis shows dense lymphoid infiltrates with prominent germinal centers, meaning organized clusters of immune cells that resemble what you would see in a reactive lymph node rather than a cancerous one.10PubMed. Borrelia burgdorferi-associated lymphocytoma cutis: clinicopathologic, immunophenotypic, and molecular study of 106 cases The infiltrate is typically wedge-shaped and polymorphous, meaning it contains a healthy mix of different cell types: B and T lymphocytes alongside plasma cells, eosinophils, histiocytes, and macrophages. That heterogeneous mix is a reassuring sign. A true lymphoma tends to be dominated by a single abnormal cell population, whereas a pseudolymphoma looks more like a vigorous immune response involving many players.11PubMed. Differentiation between malignant B-cell lymphomas and pseudolymphomas of the skin
Immunohistochemistry adds another layer. When pathologists stain the tissue for surface markers, lymphocytoma cutis typically tests positive for CD20, a marker of B cells, which is expected since B lymphocytes dominate the lesion. The critical finding is polyclonality: the B cells produce a mix of kappa and lambda light chains, indicating they represent many different clones of normal immune cells rather than a single malignant clone expanding out of control.12PubMed. Lymphocytoma cutis (cutaneous B-cell pseudolymphoma): study of 102 cases with emphasis on the histological characteristics and immunohistochemistry of the miliarial type A lymphoma, by contrast, is monoclonal: a single clone dominates, producing only one type of light chain.
When the picture is still ambiguous, molecular testing can settle the question. A technique that amplifies DNA from immunoglobulin heavy chain genes can detect whether the B-cell population is clonal or polyclonal. In lymphocytoma cutis, the result is polyclonal, matching the benign diagnosis.13PubMed. Vaccination-induced cutaneous pseudolymphoma This molecular approach has been shown to perform with high specificity, making it a useful tiebreaker when histology and immunostaining leave room for doubt.14PubMed. The application of a PCR technique for the detection of immunoglobulin heavy chain gene rearrangements in fresh or paraffin-embedded skin tissue
Treatment Depends on the Cause
For borrelial lymphocytoma, treatment follows Lyme disease guidelines. When the lymphocytoma is the only manifestation of infection, or when it appears alongside an erythema migrans rash, the standard approach is a course of oral antibiotics for about two weeks. Doxycycline, amoxicillin, and phenoxymethylpenicillin have all been used, and azithromycin for a shorter five-day course is an alternative.15PubMed. Treatment of borrelial lymphocytoma The 2020 joint guidelines from the American Academy of Neurology, American College of Rheumatology, and Infectious Diseases Society of America suggest oral antibiotic therapy for 14 days, though the recommendation was rated as having low-quality evidence behind it, reflecting how rare the condition is and how few randomized trials have focused on it specifically.16Clinical Infectious Diseases. AAN/ACR/IDSA 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease
The good news is that borrelial lymphocytoma responds well: the nodule typically fades within a few weeks of starting antibiotics. How quickly it resolves depends on how long it has been present before treatment begins. A lesion that has been there for months will take longer to shrink than one caught early.17PubMed. Treatment of borrelial lymphocytoma
Non-borrelial lymphocytoma cutis calls for a different approach. If a drug is the suspected trigger, stopping the medication is the obvious first step, and lesions often regress once the offending agent is removed. When the cause is a tattoo pigment or vaccination site, the situation is more complex because the triggering substance may remain embedded in the skin. For idiopathic cases and those that do not resolve on their own, treatment options span topical and injected corticosteroids, systemic agents like hydroxychloroquine, and physical modalities such as cryotherapy or excision.18Acta Dermato-Venereologica. Treatment of Cutaneous Pseudolymphoma: A Systematic Review There is no single dominant treatment protocol for non-infectious lymphocytoma, partly because the condition is uncommon enough that large comparative trials have never been done. In some cases, the lesions resolve spontaneously without any intervention.19PubMed. Miliarial-type perifollicular B-cell pseudolymphoma (lymphocytoma cutis): a misleading eruption in two women
Geographic and Demographic Patterns
Borrelial lymphocytoma has a strong geographic signature. It is overwhelmingly a European phenomenon, tied to the range of Ixodes ricinus ticks and the Borrelia species they carry, particularly B. afzelii. In North America, borrelial lymphocytoma is rare.20PubMed Central. Borrelial lymphocytoma cutis: a diagnostic dilemma The Borrelia species most common in the United States, B. burgdorferi sensu stricto, tends to produce other skin manifestations of Lyme disease, like erythema migrans, rather than lymphocytoma. This geographic gap means that clinicians in North America, India, and other non-endemic regions may have little firsthand experience recognizing the condition, which can lead to diagnostic delays or unnecessary worry about malignancy.
Demographically, borrelial lymphocytoma is more common in children than adults, and unlike many other manifestations of Lyme disease, it shows a male predominance.21SpringerLink (Wien Klin Wochenschr). Borrelial lymphocytoma Non-borrelial lymphocytoma cutis does not follow the same demographic pattern and can appear in any age group, though the drug-triggered variety naturally clusters in people taking the implicated medications.
The B-Cell and T-Cell Divide
Most discussions of lymphocytoma cutis center on B-cell pseudolymphoma, because that is the most common form. But cutaneous pseudolymphomas also come in a T-cell variety, where the dominant infiltrating cells are T lymphocytes rather than B lymphocytes. The T-cell form mimics T-cell lymphomas of the skin, like mycosis fungoides, instead of B-cell lymphomas. The diagnostic principles are similar: the clinician needs to establish that the infiltrate is reactive rather than malignant.22PubMed. Differentiation between malignant B-cell lymphomas and pseudolymphomas of the skin T-cell pseudolymphomas can be triggered by the same kinds of external provocations, including drugs and insect bites, but they are less well-characterized than their B-cell counterparts, in part because they are rarer and harder to study in large numbers.
The practical takeaway for patients is that any persistent skin nodule or plaque that does not clearly match a common dermatologic diagnosis warrants a biopsy. Neither the B-cell nor the T-cell form of pseudolymphoma has a distinctive enough appearance to be diagnosed by sight alone. Clinical clues like location, patient age, recent tick exposure, or a new medication can point the clinician in the right direction, but the final answer comes from the tissue.
When Lymphocytoma Signals Something Bigger
In the borrelial context, lymphocytoma cutis is classified as a manifestation of early localized Lyme disease.23PubMed. Borrelial lymphocytoma That label is important. “Early” and “localized” mean the infection has not yet disseminated widely through the body. But the lymphocytoma can be the only sign. Unlike erythema migrans, which is familiar to most physicians and patients, a bluish-red nodule on a child’s ear or an adult’s nipple does not scream “Lyme disease” the way a bull’s-eye rash does. If the connection is missed and the Borrelia infection goes untreated, it can progress to disseminated Lyme disease, with potential joint, neurological, and cardiac involvement.
That risk makes awareness of borrelial lymphocytoma genuinely consequential, particularly for people living in or visiting tick-endemic areas of Europe. Lyme disease is far easier to treat in its early stages, when a simple course of oral antibiotics resolves the infection, than it is once it has spread. Recognizing a lymphocytoma as a Lyme-related lesion rather than dismissing it as a mysterious lump can mean the difference between a two-week course of antibiotics and months of more complicated treatment for late-stage disease.24PubMed Central. Borrelial lymphocytoma cutis: a diagnostic dilemma
Tattoo and Vaccination-Related Lymphocytoma
One of the more unusual settings for lymphocytoma cutis is inside tattoos. Certain tattoo pigments, particularly red dyes, can provoke a localized immune reaction months or even years after the tattoo was placed. The resulting nodule sits within the tattooed area, which can make it difficult to notice until it grows large enough to distort the design. The diagnostic challenge here is the same as always: the biopsy needs to confirm that the infiltrate is polyclonal and reactive, not a lymphoma that happens to have developed in tattooed skin.25PubMed Central. Upadacitinib in refractory cutaneous pseudolymphoma: A case report
Vaccination-site pseudolymphomas follow a similar pattern. A persistent nodule forms at the injection site, sometimes months later, and molecular analysis confirms a polyclonal B-cell and T-cell pattern consistent with a reactive process rather than a malignancy.26PubMed. Vaccination-induced cutaneous pseudolymphoma These cases tend to be self-limiting, though the nodule may persist long enough to prompt a biopsy for reassurance. What makes them worth knowing about is the potential for unnecessary alarm: a firm lump appearing at a vaccine site months after the shot can send someone down a path of imaging and specialist referrals before a straightforward biopsy provides the answer.
Management of tattoo- and vaccination-related lymphocytoma is largely expectant. If the lesion is stable and confirmed benign, observation may be all that is needed. When it is cosmetically bothersome or continuing to grow, excision, intralesional corticosteroids, or cryotherapy can be considered. Removing the offending tattoo pigment is sometimes necessary but is itself a procedure with cosmetic trade-offs, and the pseudolymphoma can recur if residual pigment remains in the skin.